How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Lung Tumor Ablation Market
- By Ablation Technology: Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Laser Ablation, Irreversible Electroporation (IRE)
- By Tumor Type: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Metastatic Lung Tumors, Benign Lung Tumors
- By Guidance Modality: Computed Tomography (CT) Guided, Ultrasound Guided, Magnetic Resonance Imaging (MRI) Guided, Fluoroscopy Guided
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
- By Procedure Approach: Percutaneous Ablation, Surgical Ablation, Bronchoscopic Ablation
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Radiofrequency Ablation (RFA) leads By Ablation Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 18 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Lung Tumor Ablation Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Ablation Technology 5
Tumor Type 4
Guidance Modality 4
End User 3
Procedure Approach 3
Companies profiled
Medtronic
Johnson & Johnson (Biosense Webster)
Boston Scientific Corporation
AngioDynamics Inc.
Siemens Healthineers
Becton
Dickinson and Company (BD)
Hologic Inc.
Neuwave Medical Inc.
Accuray Incorporated
Merit Medical Systems Inc.
Terumo Corporation
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Johnson & Johnson (Biosense Webster)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AngioDynamics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Neuwave Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Accuray Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Merit Medical Systems Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →C.R. Bard
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Inc. (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Stryker Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Cook Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Endocare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,203M by 2033 · 9.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Radiofrequency Ablation (RFA)53.1
- Microwave Ablation (MWA)11.1
- Cryoablation12.8
- Laser Ablation12.8
- Irreversible Electroporation (IRE)10.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,644M → $3,064M · 8.1%
Europe$1,146M → $2,365M · 9.5%
Asia Pacific$1,046M → $2,139M · 9.3%
Latin America$647.8M → $1,353M · 9.6%
Middle East and Africa$498.3M → $992.8M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.322026
9.342027
9.352028
9.352029
9.362030
9.382031
9.402032
9.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic14.1
- Johnson & Johnson (Biosense Webster)20.0
- Boston Scientific Corporation9.8
- AngioDynamics Inc.9.4
- Siemens Healthineers12.4
- Becton6.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Ablation Technology11.8%
Tumor Type11.7%
Guidance Modality30.3%
End User30.6%
Procedure Approach15.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe23.9
- Asia Pacific21.6
- Latin America13.7
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 96 | 98 | 77 | 94 | 80 | 82 | 88 |
| Johnson & Johnson (Biosense Webster) | 68 | 77 | 73 | 79 | 87 | 81 | 78 |
| Boston Scientific Corporation | 63 | 85 | 87 | 87 | 87 | 67 | 79 |
| AngioDynamics Inc. | 68 | 65 | 68 | 68 | 71 | 75 | 69 |
| Siemens Healthineers | 55 | 72 | 56 | 66 | 69 | 61 | 63 |
| Becton | 61 | 62 | 65 | 50 | 67 | 69 | 62 |
| Dickinson and Company (BD) | 51 | 61 | 44 | 46 | 53 | 50 | 51 |
| Hologic Inc. | 48 | 43 | 40 | 44 | 37 | 54 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Johnson & Johnson (Biosense Webster)
- Boston Scientific Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Johnson & Johnson (Biosense Webster) | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Boston Scientific Corporation | ◐ | ◐ | ◐ | ✓ | ✓ | − |
| AngioDynamics Inc. | ✓ | ◐ | − | ✓ | ◐ | ◐ |
| Siemens Healthineers | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Becton | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Dickinson and Company (BD) | ◐ | ◐ | − | ◐ | ◐ | − |
| Hologic Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic88
2Boston Scientific Corporation79
3Johnson & Johnson (Biosense Webster)78
4AngioDynamics Inc.69
5Siemens Healthineers63
6Becton62
7Dickinson and Company (BD)51
8Hologic Inc.44
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
MedtronicJohnson & Johnson (Biosense Webster)Boston Scientific Corporation
Challenger1
Strong scale, closing on the leaders.
AngioDynamics Inc.
Contender2
Focused players with pockets of strength.
Siemens HealthineersBecton
Niche2
Specialists in a single segment or region.
Dickinson and Company (BD)Hologic Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Ablation Technology in North America, then scale across Lung Tumor Ablation Market — a $352M beachhead inside a $5.58B market.
Beachhead (SOM)$352Mobtainable near-term
Serviceable (SAM)$2.01Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Radiofrequency Ablation (RFA)
Best fit — highest urgency & budget in Ablation Technology.
Economic buyer77 fit
Microwave Ablation (MWA)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Cryoablation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Ablation Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tumor Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Guidance Modality
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel26%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Ablation Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Lung Tumor Ablation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation12%
Closed-won6%
$8.7KCAC
$35KLTV
4.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Lung Tumor Ablation Market is a durable-growth opportunity — $4.23B by 2033, compounding at 6.0%.
TAM · 2025$2.66Btoday
TAM · 2033$4.23Bforecast
CAGR6.0%2027–2033
Cumulative$30.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.23BTotal addressable market
SAM$1.45BServiceable available market
SOM$256MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.0% CAGR
Demand compounds through 2033, outpacing GDP across Ablation Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Ablation Technology moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.23BLarge & growingTAM by 2033 at 6.0% CAGR
$1.45BServiceable nowreachable with today’s model
$256MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.30BBear3.9% CAGR
$4.23BBase6.0% CAGR
$5.42BBull7.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tumor Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Lung Tumor Ablation Market — a $1.44B market by 2033. Plan: grow share from 10.9% to 16.8%.
Market size · 2033$1.44Btotal addressable
Market CAGR6.9%2027–2033
Target share16.8%from 10.9% today
Revenue ambition$243Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.9% | 16.8% | On track |
| Revenue | $143M | $243M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 35.5% | 40.4% | On track |
| Customer retention | 89.2% | 95.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Ablation Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tumor Type capability
A defensible second engine — invest in Tumor Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Ablation Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tumor Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $29M capacity & capability investment
- Greenlight bolt-on M&A in Tumor Type
- Authorise North America expansion plan
- Fund R&D program for Ablation Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Lung Tumor Ablation Market conversation — a $2.28B market you can size, segment and defend in minutes.
Market size · 2033$2.28Btotal opportunity
Growth10.5%CAGR to 2033
Addressable buyers1,008+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Ablation Technology
Goal Grow share in Ablation Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 3 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
MedtronicJohnson & Johnson (Biosense Webster)Boston Scientific CorporationAngioDynamics Inc.Siemens HealthineersBectonDickinson and Company (BD)Hologic Inc.+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Lung Tumor Ablation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Lung Tumor Ablation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Lung Transplant Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportLungs in Vitro Model Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportLung Simulators Market
Lung Simulators Market is valued at USD 455 Million in 2025 and is expected to reach USD 785 Mi…
$455M market · 2025 base year
View reportLung Pulmonary Airway Disease Treatment Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportLung-on-a-chip Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportLung Improvement Peak Flow Meter Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportLung Function Test Calibration Gas Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportLung Function Monitor Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportLung Exercise Machine Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportLung Disease Therapeutics Market
Market size, share, segmentation and regional forecast.
$302M market · 2025 base year
View reportLung Disease Therapeutic Drug Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportLung Demonstration Models Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.